<DOC>
	<DOCNO>NCT00921869</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) , safety , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) anti-tumor activity E7050 administer orally twice daily patient advance solid tumor .</brief_summary>
	<brief_title>A Study E7050 Administered Orally Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>Phase I , open-label , dose-escalation study determine maximum tolerate dose ( MTD ) E7050 give orally , twice-daily , patient advance tumor progress follow effective therapy .</detailed_description>
	<criteria>Inclusion criterion : 1 . Subjects histological cytological diagnosis solid tumor gastric cancer . 2 . Subjects progress treatment approve therapy standard effective therapy available . 3 . Subjects adequate organ function . 4 . Patients carryover effect prior therapy adverse drug reaction ( exclude alopecia ) may affect safety evaluation investigational drug . 5 . Subjects Performance Status ( PS ) 01 establish Eastern Cooperative Oncology Group ( ECOG ) . Exclusion criterion : 1 . Subjects brain metastases clinical symptom require treatment . 2 . Subjects serious complication disease history . 3 . Subjects take oral medication . 4 . Subjects need continuous use drug food strongly inhibit induce CYP3A4/5 CYP2D6 study period . 5 . Female subject pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Gastrointestinal Cancer</keyword>
</DOC>